Christopher Sakellis, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Somatostatin | 2 | 2024 | 138 | 0.990 |
Why?
|
| Neuroendocrine Tumors | 2 | 2024 | 659 | 0.600 |
Why?
|
| Positron-Emission Tomography | 12 | 2024 | 6550 | 0.550 |
Why?
|
| Umbilicus | 1 | 2015 | 38 | 0.500 |
Why?
|
| Hernia, Abdominal | 1 | 2015 | 58 | 0.490 |
Why?
|
| Fluorodeoxyglucose F18 | 10 | 2022 | 2028 | 0.460 |
Why?
|
| Radiopharmaceuticals | 10 | 2024 | 2702 | 0.430 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2019 | 20741 | 0.290 |
Why?
|
| Melanoma | 2 | 2015 | 5702 | 0.170 |
Why?
|
| Cyclobutanes | 1 | 2020 | 57 | 0.170 |
Why?
|
| Carboxylic Acids | 1 | 2020 | 91 | 0.170 |
Why?
|
| Carcinoma, Merkel Cell | 2 | 2013 | 329 | 0.150 |
Why?
|
| Octreotide | 1 | 2018 | 156 | 0.140 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 4892 | 0.140 |
Why?
|
| Biological Products | 1 | 2025 | 948 | 0.120 |
Why?
|
| Nuclear Medicine | 1 | 2018 | 262 | 0.120 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2025 | 1502 | 0.120 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 648 | 0.120 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2025 | 1433 | 0.120 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 21178 | 0.120 |
Why?
|
| Kidney Neoplasms | 3 | 2019 | 4282 | 0.110 |
Why?
|
| Radiotherapy | 2 | 2018 | 1500 | 0.110 |
Why?
|
| Diagnostic Imaging | 2 | 2017 | 3530 | 0.090 |
Why?
|
| Colon | 1 | 2019 | 1797 | 0.090 |
Why?
|
| Diagnosis, Differential | 5 | 2020 | 12986 | 0.090 |
Why?
|
| Lymphoma, Follicular | 1 | 2013 | 460 | 0.080 |
Why?
|
| Barium Sulfate | 1 | 2009 | 180 | 0.080 |
Why?
|
| Pancreatitis | 1 | 2015 | 1087 | 0.080 |
Why?
|
| Genital Neoplasms, Female | 1 | 2014 | 535 | 0.080 |
Why?
|
| Endometrial Neoplasms | 1 | 2017 | 1381 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2563 | 0.070 |
Why?
|
| Radiation Injuries | 1 | 2013 | 1196 | 0.070 |
Why?
|
| Leukemia | 1 | 2012 | 1518 | 0.060 |
Why?
|
| Blood Glucose | 1 | 2018 | 6421 | 0.050 |
Why?
|
| Lymphoma | 1 | 2012 | 1896 | 0.050 |
Why?
|
| Aged, 80 and over | 6 | 2025 | 59548 | 0.050 |
Why?
|
| Tissue Distribution | 2 | 2018 | 2275 | 0.050 |
Why?
|
| Humans | 19 | 2025 | 767040 | 0.050 |
Why?
|
| Contrast Media | 2 | 2019 | 5329 | 0.050 |
Why?
|
| Antigens, CD19 | 1 | 2025 | 443 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 9410 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 7435 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2015 | 4745 | 0.040 |
Why?
|
| Technetium Tc 99m Medronate | 1 | 2019 | 134 | 0.040 |
Why?
|
| Image Enhancement | 1 | 2009 | 2867 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 9245 | 0.040 |
Why?
|
| Consent Forms | 1 | 2018 | 55 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 11097 | 0.030 |
Why?
|
| Neoplasms | 3 | 2018 | 22350 | 0.030 |
Why?
|
| Intestinal Neoplasms | 1 | 2018 | 314 | 0.030 |
Why?
|
| Artifacts | 2 | 2018 | 1904 | 0.030 |
Why?
|
| Female | 8 | 2025 | 396660 | 0.030 |
Why?
|
| Radioimmunotherapy | 1 | 2013 | 93 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2012 | 5859 | 0.030 |
Why?
|
| Retrospective Studies | 5 | 2025 | 81659 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 11217 | 0.020 |
Why?
|
| Male | 7 | 2025 | 364203 | 0.020 |
Why?
|
| Remission Induction | 1 | 2017 | 2408 | 0.020 |
Why?
|
| Urinary Tract | 1 | 2013 | 305 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2013 | 1987 | 0.020 |
Why?
|
| Necrosis | 1 | 2013 | 1614 | 0.020 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2013 | 734 | 0.020 |
Why?
|
| Adult | 6 | 2025 | 223317 | 0.020 |
Why?
|
| Middle Aged | 6 | 2025 | 223233 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 2018 | 1481 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2013 | 837 | 0.020 |
Why?
|
| Aged | 5 | 2025 | 171319 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2017 | 2594 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2009 | 1587 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2013 | 1811 | 0.020 |
Why?
|
| Stomach | 1 | 2009 | 701 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2025 | 65295 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 36582 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2013 | 2587 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 6844 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2009 | 1372 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 2009 | 1383 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2009 | 4026 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 5446 | 0.010 |
Why?
|
| Intestines | 1 | 2009 | 1905 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 12536 | 0.010 |
Why?
|
| Disease Progression | 1 | 2016 | 13646 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 2016 | 5186 | 0.010 |
Why?
|
| Lung | 1 | 2013 | 10076 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 11872 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 9108 | 0.010 |
Why?
|
| Brain | 1 | 2013 | 27163 | 0.000 |
Why?
|
| Prospective Studies | 1 | 2009 | 54886 | 0.000 |
Why?
|
| Young Adult | 1 | 2009 | 59980 | 0.000 |
Why?
|